Promising Growth Prospects for Argenx Se’s Vyvgart in CIDP and gMG Treatment Drive Buy Rating

Bank of America Securities analyst Tazeen Ahmad has maintained their bullish stance on ARGX stock, giving a Buy rating on June 16.

Tazeen Ahmad’s rating is based on the promising growth prospects of Argenx Se’s Vyvgart, particularly in the treatment of CIDP and gMG. The expert neurologist consulted in the report highlighted Vyvgart’s favorable safety profile and its efficacy, which is either superior or comparable to existing treatments like IVIg. This has led to a significant uptake, especially among patients who have not responded well to IVIg, and the expectation is that Vyvgart could capture a 50% market share in CIDP over time.
Additionally, Vyvgart’s role in treating gMG is expanding, with a notable portion of patients being treated with biologics, and Vyvgart is becoming the biologic of choice due to its efficacy and safety. The anticipated approval of the pre-filled syringe (PFS) is expected to further boost Vyvgart’s adoption, particularly in rural areas and large hospitals where infusion coordination is challenging. These factors contribute to the confidence in Vyvgart’s growth and support the Buy rating with a price objective of $804.

In another report released on June 16, Wedbush also maintained a Buy rating on the stock with a $715.00 price target.

ARGX’s price has also changed moderately for the past six months – from $628.320 to $540.760, which is a -13.94% drop .